E. McDonald

发表

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

A. Molla, S. Vasavanonda, D. Norbeck, 1998, Journal of medicinal chemistry.

Evaluation of furofuran as a P2 ligand for symmetry-based HIV protease inhibitors

S. Vasavanonda, D. Norbeck, D. Kempf, 1996 .

Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides

P. Fernandes, C. Vojtko, D. Hardy, 1988, Antimicrobial Agents and Chemotherapy.

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

S. Vasavanonda, D. Norbeck, D. Kempf, 1995, Proceedings of the National Academy of Sciences of the United States of America.

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Dale J. Kempf, John M. Leonard, Jacob J. Plattner, 1998, Antimicrobial Agents and Chemotherapy.

In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide

R. R. Bower, R. Bailer, P. Fernandes, 1986, Antimicrobial Agents and Chemotherapy.

Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease

A. D. Rodrigues, S. Muchmore, A. Molla, 1997 .

Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model

R. Bailer, P. Fernandes, R. Swanson, 1987, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

A. D. Rodrigues, J. Leonard, A. Hsu, 1997, Antimicrobial agents and chemotherapy.

Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography.

K. Marsh, E. McDonald, E. Eiden, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Synthesis and antitumor activity of structural analogues of the epipodophyllotoxins.

J. Clement, E. McDonald, J. Plattner, 1991, Journal of Medicinal Chemistry.

Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.

S. Vasavanonda, H. Sham, T. Robins, 1995, Biochemical and biophysical research communications.

New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance

P. Fernandes, D. Hardy, E. McDonald, 1989, Antimicrobial Agents and Chemotherapy.

Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

V. Stoll, S. Vasavanonda, D. Norbeck, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.

S. Vasavanonda, D. Norbeck, D. Kempf, 2003, Bioorganic & medicinal chemistry letters.

Effect of dosing intervals on efficacy of clarithromycin and erythromycin in mouse infection models.

P. Fernandes, R. Swanson, D. Hardy, 1988, Drugs under experimental and clinical research.

Synthesis and antitumour activities of quinolone antineoplastic agents.

J. Clement, E. McDonald, J. Plattner, 1992, Drugs under experimental and clinical research.

A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

A. Molla, S. Vasavanonda, N. Lyons, 1996, Journal of medicinal chemistry.